Skip to content
November 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Chemotherapy and Targeted Therapy
  • DEA Escalates Regulatory Crackdown on Synthetic Kratom Derivatives: A New Era of Enforcement
  • Chemotherapy and Targeted Therapy

DEA Escalates Regulatory Crackdown on Synthetic Kratom Derivatives: A New Era of Enforcement

Nana Muazin November 16, 2026 7 minutes read
dea-escalates-regulatory-crackdown-on-synthetic-kratom-derivatives-a-new-era-of-enforcement

In a significant regulatory shift aimed at curbing the proliferation of potent, lab-engineered substances, the U.S. Drug Enforcement Administration (DEA) has officially moved to place three synthetic alkaloids associated with Mitragyna speciosa—commonly known as kratom—into Schedule I of the Controlled Substances Act (CSA). The move, finalized in late August 2026, marks an aggressive escalation in the federal government’s oversight of the rapidly evolving kratom-adjacent market.

As of August 25, 2026, the synthetic substances mitragynine pseudoindoxyl, MGM-15, and MGM-16 are officially classified as Schedule I controlled substances. This designation places them in the same category as heroin and LSD, reserved for drugs deemed to have a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision.

The Chronology of Federal Intervention

The regulatory trajectory began in earnest on July 1, 2026, when the DEA published two critical notices in the Federal Register, signaling its intent to exercise emergency scheduling authority. The agency cited the "imminent hazard to public safety" posed by the rising availability of synthetic, high-potency derivatives that mimic or exceed the opioid-like effects of naturally occurring kratom alkaloids.

Following the mandatory 30-day public comment period, the Office of the Assistant Secretary for Health (OASH) synthesized feedback and provided it to the Attorney General. By August 25, 2026, the DEA had completed its review, officially issuing the temporary scheduling order. This order, effective immediately, applies to all isomers, esters, ethers, and salts of the identified substances. The temporary placement is set for an initial two-year period, with the possibility of a one-year extension, providing the federal government time to evaluate whether permanent scheduling is warranted or if the substances fall under existing exemptions through the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Understanding the Targeted Substances

The DEA’s intervention is specifically aimed at "semi-synthetic" and "synthetic" derivatives. While natural kratom contains mitragynine and 7-hydroxymitragynine (7-OH), the market has seen a surge in modified versions engineered in laboratories to produce more intense, concentrated psychoactive effects.

  • Mitragynine Pseudoindoxyl: A chemical rearrangement product of 7-OH. It exhibits significantly higher potency than its natural precursors.
  • MGM-15: A synthetic derivative of 7-OH that has demonstrated potent opioid-like properties in preclinical models.
  • MGM-16: The 9-fluoro derivative of mitragynine pseudoindoxyl. Though not yet widely marketed, its high potency and potential for severe public health consequences prompted the DEA to include it in the preemptive ban.

According to federal health authorities, these substances function as mu-opioid receptor (MOR) agonists. Their chemical structure creates a high affinity for receptors in the brain, inducing effects similar to morphine and fentanyl, including the risk of physical dependence, psychological addiction, and, most critically, respiratory depression.

Supporting Data and Public Health Rationale

The DEA’s justification for this emergency scheduling relies on three primary factors mandated by 21 U.S.C. § 811(c): the history and current pattern of abuse; the scope, duration, and significance of abuse; and the risk to public health.

The Shift in Market Dynamics

The agency noted a dangerous pivot in the marketplace. While traditional kratom leaf has been consumed for decades, the industry began introducing "standardized," high-potency, and often flavored products designed to appeal to a broader, younger demographic. By 2022, estimated prevalence of use for these types of products reached approximately 2 million individuals.

Pharmacological Potency

Preclinical data provided to the DEA painted a concerning picture of these substances. Mitragynine pseudoindoxyl was found to be approximately 100 times more potent than standard mitragynine. Furthermore, MGM-15 and MGM-16 were calculated to be 50 to 240 times more potent than morphine. These findings, combined with evidence of physical dependence in animal models, led regulators to conclude that the risk to public health was both substantial and immediate.

DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I

Deceptive Marketing

The DEA expressed alarm at the way these products were marketed to consumers. Often packaged as aids for "stress," "tension," or "mental clarity," the advertising frequently obscured the opioid-like reality of the chemicals. The "low barrier to entry"—facilitated by candy-like flavors and convenient, chewable formats—allowed these potent synthetic drugs to be sold in retail environments with no age restrictions, a clear point of failure in current consumer safety protections.

Official Responses and Regulatory Ambiguity

The Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) have corroborated the DEA’s findings, confirming that these specific synthetic substances hold no recognized medical application.

However, the regulatory landscape remains complex, particularly regarding the status of 7-hydroxymitragynine (7-OH) itself. The DEA has proposed a threshold for 7-OH, suggesting that botanical products containing 7-OH above a specific percentage (0.050% on a dry weight basis) should also be subject to regulation. This has sparked significant debate, as the term "article" in the proposed rule lacks a clear, universally accepted definition within the context of the CSA or the FD&C Act.

Legal experts, including Brian Malkin, Co-Chair of the Spencer Fane Cannabis and FDA Pharmaceutical and Biologics Market Teams, have highlighted this ambiguity. Does "article" refer to a single pill, a whole bottle, or a batch? The FDA has historically interpreted "article" as a finished product or component, but the lack of a formal definition in the DEA’s notices leaves manufacturers and distributors in a state of regulatory uncertainty.

The OASH has extended the public comment period regarding these 7-OH thresholds until September 10, 2026, signaling that the federal government is still grappling with the technicalities of defining how "natural" kratom products might cross the line into "controlled substance" status based on their chemical composition.

Implications for Industry and Research

The impact of this scheduling is immediate and far-reaching for any entity dealing with these specific compounds:

  1. Manufacturing and Distribution: All commercial sales of products containing mitragynine pseudoindoxyl, MGM-15, or MGM-16 must cease immediately. Retailers and distributors are required to surrender any existing stock.
  2. Research Constraints: Researchers wishing to study these substances are now required to obtain a specific Schedule I license. This imposes a significant bureaucratic and financial hurdle, likely slowing down legitimate scientific inquiry into the long-term effects or potential medical benefits of these compounds.
  3. Legal Liability: Any individual or company handling these substances without a valid Schedule I registration faces severe administrative, civil, and criminal sanctions under federal law.
  4. Operational Compliance: Those who do hold valid registrations must now adhere to the strict security, record-keeping, and storage requirements mandated by the DEA for all Schedule I controlled substances.

Conclusion: A Precedent for Future Oversight

The DEA’s move to place these synthetic alkaloids in Schedule I underscores a broader trend: the federal government is no longer content to wait for a public health crisis to fully manifest before intervening. By targeting the synthetic derivatives of kratom, the DEA is attempting to box in the market, distinguishing between traditional botanical use and the high-risk, lab-synthesized analogs that pose a direct, opioid-like threat to public safety.

For the kratom industry, the message is clear: the era of "gray market" semi-synthetics is ending. Businesses, researchers, and consumers alike must remain vigilant. As the deadlines for compliance have passed and the debate over 7-OH thresholds continues, stakeholders must develop robust action plans to ensure they are not caught in the crosshairs of an increasingly assertive regulatory regime. The next few years will likely be defined by how the government balances the need to curtail dangerous substances with the complex, and often murky, reality of botanical-derived pharmacology.

About the Author

Nana Muazin

Author

View All Posts

Post navigation

Previous: WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial

Related Stories

eli-lilly-continues-historic-ma-streak-with-1-5-billion-acquisition-of-calytrix-bio
  • Chemotherapy and Targeted Therapy

Eli Lilly Continues Historic M&A Streak with $1.5 Billion Acquisition of Calytrix Bio

Basiran November 16, 2026
bridging-the-transparency-gap-how-rx-almanac-is-disrupting-pharmas-word-of-mouth-vendor-culture
  • Chemotherapy and Targeted Therapy

Bridging the Transparency Gap: How Rx Almanac is Disrupting Pharma’s "Word-of-Mouth" Vendor Culture

Ammar Sabilarrohman November 16, 2026
sofinnova-partners-secures-e725-million-to-bridge-europes-biotech-scale-up-gap
  • Chemotherapy and Targeted Therapy

Sofinnova Partners Secures €725 Million to Bridge Europe’s Biotech "Scale-Up" Gap

Layla Zulfa November 16, 2026

Recent Posts

  • DEA Escalates Regulatory Crackdown on Synthetic Kratom Derivatives: A New Era of Enforcement
  • WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial
  • A Paradigm Shift in Cancer Immunotherapy: Mount Sinai Scientists Target Tumor Protectors, Not Just the Tumors Themselves
  • Aclaris Therapeutics’ Bosakitug Fails to Meet Primary Endpoints in Atopic Dermatitis Phase II Trial, Shifting Focus to Oral Kinase Inhibitors
  • Beyond the Checkbook: Unlocking Transformative Impact Through Gifts-in-Kind

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

dea-escalates-regulatory-crackdown-on-synthetic-kratom-derivatives-a-new-era-of-enforcement
  • Chemotherapy and Targeted Therapy

DEA Escalates Regulatory Crackdown on Synthetic Kratom Derivatives: A New Era of Enforcement

Nana Muazin November 16, 2026
who-halts-hydroxychloroquine-and-lopinavir-ritonavir-arms-in-global-solidarity-trial-1
  • Global Breast Cancer Awareness

WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial

Nana November 16, 2026
a-paradigm-shift-in-cancer-immunotherapy-mount-sinai-scientists-target-tumor-protectors-not-just-the-tumors-themselves
  • Medical Research and Clinical Trials

A Paradigm Shift in Cancer Immunotherapy: Mount Sinai Scientists Target Tumor Protectors, Not Just the Tumors Themselves

Dwi Wanna November 16, 2026
aclaris-therapeutics-bosakitug-fails-to-meet-primary-endpoints-in-atopic-dermatitis-phase-ii-trial-shifting-focus-to-oral-kinase-inhibitors
  • Medical Research and Clinical Trials

Aclaris Therapeutics’ Bosakitug Fails to Meet Primary Endpoints in Atopic Dermatitis Phase II Trial, Shifting Focus to Oral Kinase Inhibitors

Asep Darmawan November 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.